RecruitingPHASE2, PHASE3NCT05979051

A Study to Evaluate the Efficacy and Safety of SHR-1703 in Subjects With Eosinophilic Granulomatosis With Polyangiitis (EGPA)

Studying Eosinophilic granulomatosis with polyangiitis

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Guangdong Hengrui Pharmaceutical Co., Ltd
Intervention
SHR-1703(drug)
Enrollment
166 enrolled
Eligibility
18 years · All sexes
Timeline
20232028

Study locations (2)

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT05979051 on ClinicalTrials.gov

Other trials for Eosinophilic granulomatosis with polyangiitis

Additional recruiting or active studies for the same condition.

See all trials for Eosinophilic granulomatosis with polyangiitis

← Back to all trials